Calculate maximum safe doses of local anesthetics (lidocaine, bupivacaine, ropivacaine) with and without epinephrine, plus LAST toxicity recognition.
Local anesthetic systemic toxicity (LAST) remains one of the most feared complications in regional anesthesia and procedural sedation. Accurate weight-based dose calculation is the first step in prevention. This calculator computes maximum safe doses for six commonly used local anesthetic agents — lidocaine, bupivacaine, ropivacaine, mepivacaine, prilocaine, and chloroprocaine — with and without epinephrine.
The addition of epinephrine (typically 1:200,000 concentration) produces local vasoconstriction, slowing systemic absorption and effectively raising the maximum permissible dose. For example, lidocaine's ceiling increases from 4.5 mg/kg to 7 mg/kg with epinephrine. However, epinephrine-containing solutions should be avoided in end-artery territories (digits, ear, nose, penis) and used cautiously in patients with severe cardiovascular disease.
Beyond simple dose calculation, this tool adjusts for hepatic impairment (amide local anesthetics undergo hepatic metabolism) and advanced age (reduced hepatic blood flow and protein binding changes). It provides volume conversions at your chosen concentration, comparing onset and duration across agents, and includes a complete LAST recognition and treatment algorithm featuring 20% lipid emulsion rescue dosing.
Local anesthetic overdose is preventable with proper dose calculation. This calculator provides weight-adjusted maximum doses for all major agents, accounts for patient factors like age and liver function, and includes LAST recognition and rescue protocols — critical knowledge for emergency departments, surgical suites, dental offices, and procedural areas. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain.
Maximum Dose (mg) = Max mg/kg × weight (kg) × hepatic factor × age factor. Volume (mL) = dose (mg) ÷ concentration (mg/mL). Concentration conversion: X% solution = X × 10 mg/mL.
Result: Max dose = 490 mg, max volume = 49 mL of 1% lidocaine with epinephrine
7 mg/kg × 70 kg = 490 mg. At 1% (10 mg/mL), the maximum volume is 490 ÷ 10 = 49 mL.
Choosing the right local anesthetic depends on the clinical context. Lidocaine remains the workhorse for minor procedures, wound repair, and dental work due to its rapid onset (2-5 minutes) and moderate duration. Bupivacaine and ropivacaine are preferred for longer procedures and regional blocks where extended analgesia is needed. Chloroprocaine is uniquely suited to obstetric epidurals (rapid onset, rapid metabolism, minimal fetal exposure) and settings where short duration is desirable. Prilocaine has the highest dose ceiling among amides but carries the risk of methemoglobinemia at doses > 600 mg.
The same dose produces very different plasma levels depending on injection location. Peak plasma concentrations rank (highest to lowest): intercostal > caudal > epidural > brachial plexus > subcutaneous infiltration. A dose that is safe for subcutaneous infiltration may approach toxic levels with intercostal injection. Highly vascular areas (face, scalp, intercostal spaces) absorb anesthetic fastest.
Children require careful weight-based dosing with mandatory calculation — "eyeballing" is never acceptable. Neonates have reduced protein binding (higher free drug fraction), immature hepatic metabolism, and higher cardiac output relative to body weight, all increasing toxicity risk. Elderly patients often need 20-30% dose reductions due to decreased hepatic blood flow, reduced clearance, and increased sensitivity to nerve blockade. Patients with heart failure require caution as reduced cardiac output slows hepatic metabolism of amide anesthetics.
Epinephrine causes local vasoconstriction, slowing systemic absorption of the anesthetic. This means plasma levels rise more slowly, allowing a higher total dose before toxic concentrations are reached. Typically epinephrine 1:200,000 (5 μg/mL) is used.
Local Anesthetic Systemic Toxicity (LAST) occurs when plasma levels exceed toxic thresholds. Early signs include circumoral numbness, metallic taste, and tinnitus. Progressive toxicity causes seizures, and cardiovascular collapse (bradycardia, wide QRS, VT/VF) can follow, sometimes without preceding CNS symptoms — especially with bupivacaine.
Intravenous 20% lipid emulsion (Intralipid) is the definitive treatment for severe LAST. The lipid acts as a "sink," sequestering lipophilic anesthetic molecules from cardiac tissue. Dose: 1.5 mL/kg bolus over 1 minute, then 0.25 mL/kg/min infusion. It should be available wherever large doses of local anesthetics are administered.
No. Tumescent anesthesia uses very dilute lidocaine solutions (0.05-0.1%) in large volumes of subcutaneous fluid. The slow absorption kinetics allow much higher total doses (up to 55 mg/kg in Klein protocol) than standard infiltration. This calculator uses standard maximum dose guidelines for non-tumescent techniques.
Bupivacaine has the highest cardiac toxicity potential of the common local anesthetics due to its strong binding to cardiac sodium channels (the 'fast-in, slow-out' model). It targets the CC/CNS ratio (ratio of the dose causing cardiovascular collapse to the dose causing seizures) of bupivacaine is close to 1:1, meaning cardiac arrest can occur without warning seizures.
Yes. Pregnancy increases sensitivity to local anesthetics due to elevated progesterone (lowers neural threshold), reduced protein binding (more free drug), and engorgement of epidural veins (higher absorption risk). Doses should be reduced by approximately 25-30% during pregnancy.